252 related articles for article (PubMed ID: 35300518)
21. Equipment and analytical companies meeting continuous challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
Page T; Dubina H; Fillipi G; Guidat R; Patnaik S; Poechlauer P; Shering P; Guinn M; Mcdonnell P; Johnston C
J Pharm Sci; 2015 Mar; 104(3):821-31. PubMed ID: 25448273
[TBL] [Abstract][Full Text] [Related]
22. Biopharmaceutical Industry Approaches to Facility Segregation for Viral Safety: An Effort from the Consortium on Adventitious Agent Contamination in Biomanufacturing.
Barone PW; Avgerinos S; Ballard R; Brussel A; Clark P; Dowd C; Gerentes L; Hart I; Keumurian FJ; Kindermann J; Leung JC; Ly N; Mink S; Minning S; Mullberg J; Murphy M; Nöske K; Parriott S; Shum B; Wiebe ME; Springs SL
PDA J Pharm Sci Technol; 2019; 73(2):191-203. PubMed ID: 30361281
[TBL] [Abstract][Full Text] [Related]
23. Continuous counter-current chromatography for capture and polishing steps in biopharmaceutical production.
Steinebach F; Müller-Späth T; Morbidelli M
Biotechnol J; 2016 Sep; 11(9):1126-41. PubMed ID: 27376629
[TBL] [Abstract][Full Text] [Related]
24. Recent Advances and Future Directions in Downstream Processing of Therapeutic Antibodies.
Matte A
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955796
[TBL] [Abstract][Full Text] [Related]
25. Model-based control system design to manage process parameters in mammalian cell culture for biopharmaceutical manufacturing.
Sakaki A; Namatame T; Nakaya M; Omasa T
Biotechnol Bioeng; 2024 Feb; 121(2):605-617. PubMed ID: 37960996
[TBL] [Abstract][Full Text] [Related]
26. Antibody disulfide bond reduction and recovery during biopharmaceutical process development-A review.
Ren T; Tan Z; Ehamparanathan V; Lewandowski A; Ghose S; Li ZJ
Biotechnol Bioeng; 2021 Aug; 118(8):2829-2844. PubMed ID: 33844277
[TBL] [Abstract][Full Text] [Related]
27. Summary from Advanced Manufacturing Technology Workshop Held at 6th Accelerating Biopharmaceutical Development Meeting.
Lee KH; Mantle JL
PDA J Pharm Sci Technol; 2021; 75(1):48-63. PubMed ID: 32540863
[TBL] [Abstract][Full Text] [Related]
28. Accelerating attribute-focused process and product development through the development and deployment of autonomous process analytical technology platform system.
Wu CR; Chan B; Sarich Z; Duan Y; Chen J; Song JL; Berke M; Miranda LP; Goudar CT
Biotechnol Bioeng; 2024 Apr; 121(4):1257-1270. PubMed ID: 38328831
[TBL] [Abstract][Full Text] [Related]
29. Benchmarking biopharmaceutical process development and manufacturing cost contributions to R&D.
Farid SS; Baron M; Stamatis C; Nie W; Coffman J
MAbs; 2020; 12(1):1754999. PubMed ID: 32449439
[TBL] [Abstract][Full Text] [Related]
30. Exploring the potential of machine learning for more efficient development and production of biopharmaceuticals.
Puranik A; Dandekar P; Jain R
Biotechnol Prog; 2022 Nov; 38(6):e3291. PubMed ID: 35918873
[TBL] [Abstract][Full Text] [Related]
31. Metabolic trends of Chinese hamster ovary cells in biopharmaceutical production under batch and fed-batch conditions.
Rish AJ; Drennen JK; Anderson CA
Biotechnol Prog; 2022 Jan; 38(1):e3220. PubMed ID: 34676699
[TBL] [Abstract][Full Text] [Related]
32. QbD-guided pharmaceutical development of Pembrolizumab biosimilar candidate PSG-024 propelled to industry meeting primary requirements of comparability to Keytruda®.
Jaffar-Aghaei M; Khanipour F; Maghsoudi A; Sarvestani R; Mohammadian M; Maleki M; Havasi F; Rahmani H; Karagah AH; Kazemali MR
Eur J Pharm Sci; 2022 Jun; 173():106171. PubMed ID: 35378209
[TBL] [Abstract][Full Text] [Related]
33. Expediting online liquid chromatography for real-time monitoring of product attributes to advance process analytical technology in downstream processing of biopharmaceuticals.
Graf T; Naumann L; Bonnington L; Heckel J; Spensberger B; Klein S; Brey C; Nachtigall R; Mroz M; Hogg TV; McHardy C; Martinez A; Braaz R; Leiss M
J Chromatogr A; 2024 Aug; 1729():465013. PubMed ID: 38824753
[TBL] [Abstract][Full Text] [Related]
34. Proteomic Profiling of IgG1 Producing CHO Cells Using LC/LC-SPS-MS
Strasser L; Farrell A; Ho JTC; Scheffler K; Cook K; Pankert P; Mowlds P; Viner R; Karger BL; Bones J
Front Bioeng Biotechnol; 2021; 9():569045. PubMed ID: 33898396
[TBL] [Abstract][Full Text] [Related]
35. Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD
J Pharm Sci; 2015 Mar; 104(3):832-9. PubMed ID: 25546650
[TBL] [Abstract][Full Text] [Related]
36. Reducing biopharmaceutical manufacturing costs through continuous processing in a flexible J.POD® facility.
Garcia FA; Gefroh E
Drug Discov Today; 2023 Jul; 28(7):103619. PubMed ID: 37201779
[TBL] [Abstract][Full Text] [Related]
37. From cell line development to the formulated drug product: The art of manufacturing therapeutic monoclonal antibodies.
Carrara SC; Ulitzka M; Grzeschik J; Kornmann H; Hock B; Kolmar H
Int J Pharm; 2021 Feb; 594():120164. PubMed ID: 33309833
[TBL] [Abstract][Full Text] [Related]
38. Recent advances in technology supporting biopharmaceutical production from mammalian cells.
Butler M; Meneses-Acosta A
Appl Microbiol Biotechnol; 2012 Nov; 96(4):885-94. PubMed ID: 23053101
[TBL] [Abstract][Full Text] [Related]
39. Biomanufacturing readiness levels [BRL]-A shared vocabulary for biopharmaceutical technology development and commercialization.
Kedia SB; Baker JC; Carbonell RG; Lee KH; Roberts CJ; Erickson J; Schiel JE; Rogers K; Schaefer G; Pluschkell S
Biotechnol Bioeng; 2022 Dec; 119(12):3526-3536. PubMed ID: 36071569
[TBL] [Abstract][Full Text] [Related]
40. The art of CHO cell engineering: A comprehensive retrospect and future perspectives.
Fischer S; Handrick R; Otte K
Biotechnol Adv; 2015 Dec; 33(8):1878-96. PubMed ID: 26523782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
